Major shareholder announcement - Pharma Equity Group A/S
15 Juli 2024 - 4:22PM
UK Regulatory
Major shareholder announcement - Pharma Equity Group A/S
|
|
|
|
|
|
|
|
15 July 2024
Announcement No. 21
Major shareholder announcement - Pharma Equity Group A/S
Pharma Equity Group A/S informs that, in accordance with
Section 38 of the Capital Markets Act, the company has received
major shareholder notification that Finansmanagement ApS has
acquired shares in Pharma Equity Group A/S on 11 July 2024.
As a result, Finansmanagement ApS has increased their ownership
stake from less than 5 % to over 15% in Pharma Equity Group A/S,
and as of 11 July 2024, Finansmanagement ApS holds 19,57 % of the
voting rights and share capital in Pharma Equity Group A/S.
For further information, please contact:
Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022
2114
Christian Vinding Thomsen, Chairman of the Board of Directors of
Pharma Equity Group A/S, phone: +45 2622 7222
|
|
|
|
|
|
|
|
|
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen
stock exchange, is fully dedicated to advancing the medical
projects of its subsidiary, Reponex Pharmaceuticals A/S. With an
unwavering focus on healthcare, Pharma Equity Group's primary
objective is to bring significant value to Reponex Pharmaceuticals'
medical projects.
The company is committed to providing extensive support,
resources, and expertise to drive the development and success of
these projects. As a strategic partner, Pharma Equity Group works
closely with Reponex Pharmaceuticals, prioritizing the advancement
of innovative medical solutions and breakthrough therapies. Every
effort is currently directed towards ensuring the utmost success
and impact of Reponex Pharmaceuticals' medical projects, with an
unwavering dedication to improving global healthcare outcomes. Only
when the full potential of Reponex Pharmaceuticals has been
unfolded is the intention to explore opportunities to invest in
other companies. This approach ensures a strong commitment to the
current medical projects and their development, while – on the
longer term – remaining open to new strategic investments for
continuous growth.
|
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
